Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043560 · ClinicalTrials.gov registry record · Phase 2
Study to Treat Major Depressive Disorder With a New Medication
A Phase 2 study, sponsored by James Murrough.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT03043560 is a Phase 2 study that has completed, run by James Murrough. The registered enrollment target is 45 participants.
The verdict
NCT03043560, a Phase 2 study, has completed, sponsored by James Murrough.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga, GlaxoSmithKline; FDA-approved for the treatment of seizure disorders).
Interventions
- DRUG Placebos
- DRUG Ezogabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2019-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03043560
The ClinicalTrials.gov registry entry for NCT03043560 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Murrough, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03043560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03043560 about?
NCT03043560 is a clinical study titled "Study to Treat Major Depressive Disorder With a New Medication". This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga, GlaxoSmithKline; FDA-approved for the treatment of seizure disorders).
What is the current status of trial NCT03043560?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2017-09-25. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT03043560?
The interventions under investigation include: Placebos (DRUG), Ezogabine (DRUG).
Who is sponsoring clinical trial NCT03043560?
This trial is sponsored by James Murrough, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.